Scholar Rock (NASDAQ:SRRK) versus Inhibikase Therapeutics (NYSE:IKT) Critical Survey

Scholar Rock (NASDAQ:SRRKGet Free Report) and Inhibikase Therapeutics (NYSE:IKTGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Risk & Volatility

Scholar Rock has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Scholar Rock and Inhibikase Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scholar Rock $33.19 million 36.89 -$134.50 million ($1.95) -8.71
Inhibikase Therapeutics $120,000.00 127.00 -$18.05 million ($3.95) -0.63

Inhibikase Therapeutics has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Scholar Rock and Inhibikase Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock 0 0 4 0 3.00
Inhibikase Therapeutics 0 0 1 0 3.00

Scholar Rock presently has a consensus target price of $24.75, suggesting a potential upside of 45.76%. Inhibikase Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 993.12%. Given Inhibikase Therapeutics’ higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Scholar Rock.


This table compares Scholar Rock and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scholar Rock N/A -74.00% -52.60%
Inhibikase Therapeutics -5,886.15% -94.66% -81.99%

Institutional and Insider Ownership

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 14.0% of Inhibikase Therapeutics shares are held by institutional investors. 26.2% of Scholar Rock shares are held by insiders. Comparatively, 20.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Scholar Rock beats Inhibikase Therapeutics on 8 of the 13 factors compared between the two stocks.

About Scholar Rock

(Get Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with's FREE daily email newsletter.